Catabolite Repression Control (Crc) Gene and Pseudomonas Virulence

Case Number: TT0109

Inventor(s):

• Paul Phibbs
• Paul Hager
• David Collier

Department(s):

• Department of Microbiology and Immunology

Description:
Pseudomonas aeruginosa is a Gram-negative bacterium responsible for many deadly infections in humans. It is recognized as one of the most naturally (intrinsically) antibiotic resistant bacteria known, with the capacity to develop resistance to most known antibiotics. Dr. Paul Phibbs and his associates have developed an assay that effectively identifies compounds able to block Crc gene expression or Crc protein function. These compounds can be developed as chemotherapeutic agents for treatment or prevention of P. aeruginosa infections. The invention is valuable for screening compounds that block Crc gene or protein function and it could lead to new and more effective treatment of infections. Animal data is available.

Availability: Available for either exclusive or nonexclusive licensing

Case Manager: Mark Foley